Li Yuqin, Liu Bin, Yuan Yongxin, Qin Wei
Department of Nuclear Medicine, Suining Central Hospital, Suining, Sichuan 629000, P. R. China.
Department of Anorectal, Suining Central Hospital, Suining, Sichuan 629000, P. R. China.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2022 Dec 25;39(6):1263-1268. doi: 10.7507/1001-5515.202112035.
Prostate cancer is the most common malignant tumor in male urinary system, and the morbidity and mortality rate are increasing year by year. Traditional imaging examinations have some limitations in the diagnosis of prostate cancer, and the advent of molecular imaging probes and imaging technology have provided new ideas for the integration of diagnosis and treatment of prostate cancer. In recent years, prostate-specific membrane antigen (PSMA) has attracted much attention as a target for imaging and treatment of prostate cancer. PSMA ligand positron emission tomography (PET) has important reference value in the diagnosis, initial staging, detection of biochemical recurrence and metastasis, clinical decision-making guidance and efficacy evaluation of prostate cancer. This article briefly reviews the clinical research and application progress on PSMA ligand PET imaging in prostate cancer in recent years, so as to raise the efficiency of clinical applications.
前列腺癌是男性泌尿系统最常见的恶性肿瘤，其发病率和死亡率逐年上升。传统影像学检查在前列腺癌诊断方面存在一定局限性，分子影像探针和成像技术的出现为前列腺癌的诊疗一体化提供了新思路。近年来，前列腺特异性膜抗原（PSMA）作为前列腺癌成像和治疗的靶点备受关注。PSMA配体正电子发射断层显像（PET）在前列腺癌的诊断、初始分期、生化复发及转移灶检测、临床决策指导和疗效评估等方面具有重要参考价值。本文就近年来PSMA配体PET成像在前列腺癌中的临床研究及应用进展作一简要综述，以提高临床应用效率。
